Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Pulmonary Edema D011654 23 associated lipids
Coronary Disease D003327 70 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Pancreatitis D010195 10 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Rhinitis D012220 10 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Melanoma D008545 69 associated lipids
Asthma D001249 52 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Krishnamurthi S et al. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. 1984 Biochem. Pharmacol. pmid:6091666
Kamitani T et al. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. 1984 Eur. J. Pharmacol. pmid:6144557
Tokumura A et al. Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. 1984 J. Pharm. Pharmacol. pmid:6144763
Wang ZY [Advances in the physiopathology of platelets]. 1984 Zhonghua Nei Ke Za Zhi pmid:6099795
Knauer KA et al. Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6200443
Kazimierczak W et al. Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. 1984 Am. Rev. Respir. Dis. pmid:6201094
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
O'Flaherty JT et al. Diacylglycerols enhance human neutrophil degranulation responses: relevancy to a multiple mediator hypothesis of cell function. 1984 Biochem. Biophys. Res. Commun. pmid:6433920
Mendlovic F et al. Possible involvement of cyclooxygenase products in the actions of platelet-activating factor and of lipoxygenase products in the vascular effects of epinephrine in perfused rat liver. 1984 Biochem. Biophys. Res. Commun. pmid:6435614
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Fouque F and Vargaftig BB Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. 1984 Br. J. Pharmacol. pmid:6439269
Karlsson G and Pipkorn U Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. 1984 Eur. J. Clin. Pharmacol. pmid:6439565
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Sakamoto H et al. Stimulation of leukocyte phagocytic activity by the platelet release reaction. 1984 Pathology pmid:6462776
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Chilton FH et al. 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. 1984 J. Biol. Chem. pmid:6434535
Doebber TW et al. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6517949
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Caramelo C et al. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. 1984 Biochem. Biophys. Res. Commun. pmid:6732788
Lenihan DJ and Lee TC Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6732789
Kasuya Y et al. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. 1984 Can. J. Physiol. Pharmacol. pmid:6733593
Albert DH and Snyder F Release of arachidonic acid from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine, a precursor of platelet-activating factor, in rat alveolar macrophages. 1984 Biochim. Biophys. Acta pmid:6435681
Kelton JG et al. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. 1984 J. Lab. Clin. Med. pmid:6699475
Feuerstein G et al. Effect of platelet-activating factor on coronary circulation of the domestic pig. 1984 Am. J. Physiol. pmid:6703081
Pipkorn U et al. Effect of platelet activating factor on the human nasal mucosa. 1984 Allergy pmid:6703263
Lüthje J and Ogilvie A Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP. 1984 Biochem. Biophys. Res. Commun. pmid:6704102
Clare KA and Scrutton MC The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). 1984 Eur. J. Biochem. pmid:6705791
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Touqui L et al. Dissociation between inhibition of phospholipid methylation and production of PAF-acether by rabbit platelets. 1984 Experientia pmid:6714369
Masugi F et al. [Etiological studies of hypertension. G. APRL (antihypertensive polar renomedullary lipid)]. 1984 Nippon Rinsho pmid:6716685
Kester M et al. The potentiation of arterial contraction with platelet activating factor. 1984 Pflugers Arch. pmid:6718228
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Guay DR and Richard A Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. 1984 Drug Intell Clin Pharm pmid:6723517
Poitevin B et al. Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. 1984 Immunopharmacology pmid:6724877
Kawaguchi H and Yasuda H Platelet-activating factor stimulates phospholipase in quiescent Swiss mouse 3T3 fibroblast. 1984 FEBS Lett. pmid:6436057
Kasuya Y et al. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). 1984 J. Pharmacobio-dyn. pmid:6726619
Kramer RM et al. Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. 1984 J. Biol. Chem. pmid:6436245
Iñarrea P et al. Characteristics of the binding of platelet-activating factor to platelets of different animal species. 1984 Eur. J. Pharmacol. pmid:6510472
Kornecki E et al. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. 1984 Science pmid:6150550
Chignard M et al. Paf-acether formation and arachidonic acid freeing from platelet ether-linked glyceryl-phosphorylcholine. 1984 Biochem. Biophys. Res. Commun. pmid:6437404
Schleimer RP et al. Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. 1984 J. Allergy Clin. Immunol. pmid:6208229
Nishihira J et al. Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. 1984 Lipids pmid:6527609
Gunby P A new piece for the puzzle of inflammation. 1984 JAMA pmid:6420583
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930